Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
In the absence of an available clinical trial, would you favor regorafenib immediately post-sorafenib or nivolumab in patients with HCC?
At this point in time, given the continued encouraging data regarding the efficacy of immune checkpoint blockade in HCC coupled with the substantially lower toxicity when compared to regorafenib, I would choose off-label nivolumab in this particular scenario.
When do you consider for first-line atezolizumab for metastatic bladder cancer?
I see these patients in 2 groups, "cisplatin-ineligible" or "chemotherapy-ineligible”. In the “cisplatin- ineligible” group one may consider a carboplatin-based regimen (carboplatin plus gemcitabine or carboplatin plus taxol) or atezolizumab. In “chemotherapy-ineligible”, I consider both performanc...
Do you intentionally modify your breast cancer treatment plans for those on chronic immunosuppression to avoid secondary cancers?
This will usually depend on their clinical scenario. In case where I would recommend RNI, I will still recommend RNI and counsel on risks of second canceers. In patients with early stage lower risk or disease, one can consider partial breast irradiation if appropriate though I do counsel patients th...
What is the upper limits of anthracycline dose you are willing to give in a treatment-refractory metastatic breast cancer patient if the patient is responding to salvage weekly adriamycin after progression on multiple prior regimens?
I would not normally exceed 350-400 mg/m2. However, this is a tough situation in that the patient is treatment-refractory without many other great options and responding. According to the package insert, "the probability of developing impaired myocardial function based on a combined index of signs, ...
Do you resume immunotherapy (such as nivolumab) for metastatic melanoma after therapy-induced grade 4 hyperglycemia that has resolved?
The answer is probably yes depending on the circumstances. If on a trial then no. If SOC then could consider it and since the patient probably has the equivalent of type 1 diabetes requiring insulin supplementation then unlikely to hurt them more. If the pancreas recovered then it would be a risk be...
How would you approach a chronic phase CML patient who is responding to second generation TKI but not yet in molecular remission and is now pregnant?
If the patient is now pregnant, I would stop the TKI immediately, and initiate therapy with interferon. If that is not tolerable, I'd recommend hydroxyurea, although it will likely not control relapse into overt chronic phase.
How do you manage a patient with a history of non-seminomatous germ cell tumor who has a rising AFP after primary chemotherapy without any imaging evidence of recurrence?
It would depend on the timing of the rise of AFP after chemotherapy, how elevated it is, whether they were good or poor risk patients at the time of chemotherapy, whether they had liver disease and whether the AFP was definitively elevated prior to chemo In most cases, we sort of ignore AFP < 25 or ...
For male patients in chronic phase CML on a TKI and not yet in a MMR, is there a preferred amount of time spent in a MMR before discontinuing TKI therapy to conceive or bank sperm ?
Hard to answer this one. My preference would be that the patient be in MMR confirmed by two readings three months apart before experiencing a dose interruption.
Would you ever omit adjuvant therapy for rectal cancer in patients who underwent primary resection (TME), without any neoadjuvant therapy?
What is your approach to the upfront treatment of anaplastic large cell lymphoma, ALK positive, with low IPI score in a young person?
ALK positive ALCL is the most responsive of the aggressive PTCL’s to chemotherapy, and the majority of young patients can be cured with an anthracycline containing chemotherapy regimen. Either CHOP or CHOEP (ie CHOP plus etoposide) are frequently used. In a young healthy patient I favor CHOEP based ...